Covid vaccine deaths review sent to top of FDA, but with far less certain conclusions, sources say

Eli Lilly’s triple-G obesity readout; The latest Endpoints 100 results; Public biotechs cash in; and more

Welcome back to another edition of Endpoints Weekly. We’re barreling toward the holiday season, which means it’s time for an early programming note: Our newsletters

340B sales grew 23% last year, and court battle over pilot program intensifies

Eligible health centers purchased $81.4 billion in discounted drugs under the federal 340B program in 2024, an increase of 23% from the previous year as

A 2-speed payer transformation is underway

Health insurers are facing two colliding forces heading into 2026: Medical costs are challenging the way they do business, and major technology shifts are finally

CHMP calls to reject Anavex’s Alzheimer’s pill over impurities, side effects and weak efficacy

As part of a batch of recommendations issued Friday, the European Medicines Agency’s human medicines committee (CHMP) recommended rejecting Anavex’s Alzheimer’s disease drug, issuing a

#SABCS25: Celcuity further details Phase 3 win; Relay’s PI3Kα inhibitor’s consistent performance; and more

Roche and BioNTech stole the show at this year’s San Antonio Breast Cancer Symposium. The Swiss drugmaker unveiled Phase 3 data for its oral SERD